Literature DB >> 24173203

The use of the Er:YAG 2940nm laser associated with amorolfine lacquer in the treatment of onychomycosis.

Orlando Oliveira de Morais1, Izelda Maria Carvalho Costa, Ciro Martins Gomes, Dayane Higa Shinzato, Guilherme Marreta Cavalcanti Ayres, Rayane Marques Cardoso.   

Abstract

Onychomycosis is a common disease, accounting for up to 50% of all ungual pathologies. We have been developing a clinical trial (ClinicalTrials.gov: NCT01528813) using a 2940nm Er:YAG laser to fractionally ablate human nails in vivo, aiming to increase topical amorolfine lacquer delivery to the nail unit, increasing the efficacy of topical treatment of distal and lateral subungual onychomycosis. Partial results have shown an increase in areas of nail plate free of disease. We believe that ablative lasers can increase the efficacy of topical onychomycosis treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24173203      PMCID: PMC3798374          DOI: 10.1590/abd1806-4841.20131932

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  4 in total

Review 1.  New therapeutic options for onychomycosis.

Authors:  Aditya K Gupta; Fiona C Simpson
Journal:  Expert Opin Pharmacother       Date:  2012-04-25       Impact factor: 3.889

2.  Ablation of human nail by pulsed lasers.

Authors:  J Neev; J S Nelson; M Critelli; J L McCullough; E Cheung; W A Carrasco; A M Rubenchik; L B Da Silva; M D Perry; B C Stuart
Journal:  Lasers Surg Med       Date:  1997       Impact factor: 4.025

3.  Nail abrasion.

Authors:  N Di Chiacchio; B V Kadunc; A R T de Almeida; C L Madeira
Journal:  J Cosmet Dermatol       Date:  2003-07       Impact factor: 2.696

4.  Effects of foot care intervention including nail drilling combined with topical antifungal application in diabetic patients with onychomycosis.

Authors:  Masuko Sumikawa; Takako Egawa; Ikumi Honda; Yoko Yamamoto; Yasuyuki Sumikawa; Minoru Kubota
Journal:  J Dermatol       Date:  2007-07       Impact factor: 4.005

  4 in total
  8 in total

1.  The association of fractional CO2 laser 10.600nm and photodynamic therapy in the treatment of onychomycosis.

Authors:  Guilherme Bueno de Oliveira; João Roberto Antonio; Carlos Roberto Antonio; Fernanda Alves Tomé
Journal:  An Bras Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.896

Review 2.  Efficacy of laser therapy combined with topical antifungal agents for onychomycosis: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Jianfeng Zhang; Peng Lin; Junchen Li; Chenqi Guo; Jingbo Zhai; Yu Zhang
Journal:  Lasers Med Sci       Date:  2022-04-29       Impact factor: 2.555

3.  Combination therapy for onychomycosis using a fractional 2940-nm Er:YAG laser and 5 % amorolfine lacquer.

Authors:  Jing Zhang; Sha Lu; Huaiqiu Huang; Xiqing Li; Wenying Cai; Jianchi Ma; Liyan Xi
Journal:  Lasers Med Sci       Date:  2016-06-23       Impact factor: 3.161

4.  Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2014-03-24

5.  Clearance of Recalcitrant Onychomycosis Following Q-switched Nd-Yag Laser.

Authors:  Vijay Zawar; Aarti Sarda; Abhishek De
Journal:  J Cutan Aesthet Surg       Date:  2017 Oct-Dec

Review 6.  Therapy of Skin, Hair and Nail Fungal Infections.

Authors:  Roderick Hay
Journal:  J Fungi (Basel)       Date:  2018-08-20

7.  Fractional CO2 laser ablation leads to enhanced permeation of a fluorescent dye in healthy and mycotic nails-An imaging investigation of laser-tissue effects and their impact on ungual drug delivery.

Authors:  Vinzent Kevin Ortner; Nhi Nguyen; Jonathan R Brewer; Vita Solovyeva; Merete Haedersdal; Peter Alshede Philipsen
Journal:  Lasers Surg Med       Date:  2022-04-22

Review 8.  Laser Therapy for Onychomycosis: Fact or Fiction?

Authors:  Lucette Teel Liddell; Ted Rosen
Journal:  J Fungi (Basel)       Date:  2015-04-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.